News
From July 27 to 28, the Economic and Humanitarian Forum took place in Saint Petersburg as part of the Second ...
31.07.2023
Avineiro company of the ChemRar Group announces that it has received a registration certificate from the Russian ...
10.07.2023
Elpida, the Russian developer of ELPIDA®, an innovative eslulfavarinin-based drug against HIV, has reduced the price ...
22.06.2023
Recently, the Government of the Russian Federation approved the Concept of Technological Development until 2030, ...
06.06.2023
Avineuro, a participant of the NeuroNet National Technology Initiative, has completed clinical trials of AVIANDRⓇ, an ...
29.05.2023
On May 23, a meeting of the Medicinal Chemistry Scientific Council of the Russian Academy of Sciences was held at the ...
24.05.2023
On April 29 to May 6, representatives of ChemRar Group visited Morocco. The delegation took part in “Medical Expo ...
07.05.2023
On April 26 to 28, the Invest Ethiopia 2023 forum in Addis Ababa was held to attract foreign direct investments to ...
29.04.2023
API-Technology, a part of ChemRar Group, is launching a project to scale up the production of active pharmaceutical ...
24.04.2023
Favipiravir, developed in Japan to treat influenza and other RNA-viral infections, in 2020–2022 was widely used to ...
17.01.2023
Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly ...
27.12.2021
Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was rated by Rospatent among ...
17.06.2021